Eagle Pharmaceuticals, Inc. (EGRX)
NASDAQ: EGRX · IEX Real-Time Price · USD
4.080
+0.130 (3.29%)
Jun 20, 2024, 3:45 PM EDT - Market open

Eagle Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20222021202020192018 2017 - 2012
Net Income
35.64-8.6311.9914.3131.9
Upgrade
Depreciation & Amortization
13.274.814.774.653.67
Upgrade
Share-Based Compensation
16.4519.5624.762219.08
Upgrade
Other Operating Activities
-14.6612.497.9915.02-2.27
Upgrade
Operating Cash Flow
50.728.2249.555.9952.38
Upgrade
Operating Cash Flow Growth
79.67%-42.99%-11.59%6.88%-11.09%
Upgrade
Capital Expenditures
-0.18-0.32-0.75-0.78-0.13
Upgrade
Acquisitions
-74.150000
Upgrade
Change in Investments
-12.5-5-17.500
Upgrade
Investing Cash Flow
-86.83-5.32-18.25-0.78-0.13
Upgrade
Share Issuance / Repurchase
-16.26-18.82-31.35-17.7-64.49
Upgrade
Debt Issued / Paid
11.4-8-5-6.33-3.75
Upgrade
Other Financing Activities
-1.36-1.58-1.53-0.2-19.88
Upgrade
Financing Cash Flow
-6.21-28.39-37.87-24.23-88.12
Upgrade
Net Cash Flow
-42.34-5.5-6.6230.98-35.87
Upgrade
Free Cash Flow
50.5227.948.7555.2152.25
Upgrade
Free Cash Flow Growth
81.11%-42.78%-11.70%5.66%-4.10%
Upgrade
Free Cash Flow Margin
15.96%16.26%25.96%28.18%24.50%
Upgrade
Free Cash Flow Per Share
3.912.143.624.013.54
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).